86. 肺動脈性肺高血圧症
[臨床試験数:1,083,薬物数:667(DrugBank:122),標的遺伝子数:98,標的パスウェイ数:185

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-132142
01/4/201303/06/2013ACT-385781A PAH Post-marketing studyA Post-marketing, Open-label-study ACT-385781A in patients with pulmonary arterial hypertension Pulmonary arterial hypertension (PAH)Intervention name : ACT-385781A
INN of the intervention : Epoprostenol
Dosage And administration of the intervention : A commercially available epoprostenol sodium preparation will be switched to the study drug at the same dose
Actelion Pharmaceuticals Japan Ltd.NULL20BOTH5Phase 4NULL
2EUCTR2010-018320-10-ES
(EUCTR)
26/12/201121/11/2011An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epoprostenol for injection)An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH)Extension del estudio AC-066A301, abierta, para investigar la seguridad y la tolerabilidad de ACT-385781A en pacientes con Hipertension Arterial Pulmonar (HAP) - EPITOME-2 Extension Hipertension Arterial Pulmonar
MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
40France;Canada;Belgium;Spain;Netherlands;Italy
3EUCTR2010-018320-10-IT
(EUCTR)
04/11/201101/03/2012An extension of study AC-066A301 to investigate safety and tolerabilityof the study medication (epoprostenol for injection)Estensione in aperto dello studio AC-066A301 per valutare la sicurezza e la tollerabilita' dell’ACT-385781A nei pazienti affetti da ipertensione arteriosa polmonare (IAP) - EPITOME-2 Extension Pulmonary Arterial Hypertension
MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenolo per iniezione
INN or Proposed INN: EPOPROSTENOL SODIUM
Other descriptive name: NA
Trade Name: Epoprostenolo per iniezione
INN or Proposed INN: EPOPROSTENOL SODIUM
Actelion Pharmaceuticals Ltd.NULLNot RecruitingFemale: yes
Male: yes
40Canada;Spain;Belgium;Netherlands;Italy
4NCT01462565
(ClinicalTrials.gov)
November 1, 201113/10/2011Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.)Hypertension, PulmonaryDrug: current marketed FLOLAN (epoprostenol sodium);Drug: new thermo stable formulation of epoprostenol sodiumGlaxoSmithKlineNULLCompleted18 Years75 YearsAll16Phase 4United States;Canada;Netherlands
5EUCTR2010-018320-10-NL
(EUCTR)
11/07/201112/05/2011An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epoprostenol for injection)An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH) - EPITOME-2 Extension Pulmonary Arterial Hypertension
MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
40France;Canada;Belgium;Spain;Netherlands;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2010-018322-40-NL
(EUCTR)
11/07/201119/07/2011A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 Pulmonary Arterial Hypertension
MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
35Phase 3bNetherlands;Belgium;France;Spain;Italy
7EUCTR2010-018322-40-ES
(EUCTR)
17/06/201103/11/2011Estudio de investigación clínica para evaluar la seguridad de cambiar el Flolan por un nuevo fármaco llamado Epoprostenol-Actelion en pacientes que padecen hipertensión arterial pulmonarEstudio de fase 3b multicéntrico, de una única rama, abierto para evaluar los efectos de cambiar de Flolan® a ACT-385781A en pacientes con hipertensión arterial pulmonar // A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 Hipertensión Arterial Pulmonar (HAP)
MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODICO
Other descriptive name: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODICO
Other descriptive name: EPOPROSTENOL SODIUM
Actelion Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
35Phase 3bFrance;Canada;Belgium;Spain;Netherlands;Italy
8EUCTR2010-018322-40-BE
(EUCTR)
02/07/201007/04/2010A clinical research study to evaluate the safety of changing from Flolan to a new drug called Epoprostenol-Actelion in patients suffering from pulmonary arterial hypertensionA Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 Pulmonary Arterial Hypertension
MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
40Phase 3France;Canada;Spain;Belgium;Netherlands;Italy
9EUCTR2010-018320-10-BE
(EUCTR)
02/07/201013/04/2010An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epoprostenol for injection)An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH) - EPITOME-2 Extension Pulmonary Arterial Hypertension
MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
Trade Name: Epoprostenol for injection
Product Name: Epoprostenol for injection
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLNot RecruitingFemale: yes
Male: yes
40France;Canada;Spain;Belgium;Netherlands;Italy
10EUCTR2010-018322-40-FR
(EUCTR)
20/05/201029/03/2010A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2 Pulmonary Arterial Hypertension
MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension
Trade Name: Epoprostenol-Actelion
Product Name: Epoprostenol-Actelion
Product Code: ACT-385781A
INN or Proposed INN: EPOPROSTENOL SODIUM
ACTELION Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 3bNetherlands;Belgium;France;Spain;Italy